BIOMAT Database Logo BIOMAT Database Logo

Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS. 1990

M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
Rockefeller University, New York, NY 10021.

Parenteral drug abusers are the second largest group at risk for developing AIDS (25% of US cases) and a major risk group for infection with both hepatitis B virus (HBV) and the HBV-dependent RNA hepatitis delta virus (HDV). This study was conducted to determine the prevalence in 1984-1985 and relationships of HDV and HBV infections in 372 unselected parenteral drug abusers without AIDS or symptoms related to human immunodeficiency virus type 1 (HIV-1) infection (but 49% of whom were positive for HIV-1 antibodies) and in 53 drug abusers hospitalized with AIDS. The prevalence of HDV markers in the combined study groups was 20%; 81% of study subjects with hepatitis B surface antigenemia (HBsAg) had one marker for HDV infection. Significant differences were found between patients with and without AIDS with respect to the prevalence of hepatitis delta antigen (5.7% vs. 0.8%, P less than .05) and antibody (0 vs. 21.4%, P less than .01) and HBsAg (15.1% vs. 5.1%, P less than .05). The significantly higher prevalence of hepatitis delta antigen and HBsAg in subjects with AIDS suggests that persistence or reactivation of these viruses is significantly greater among parenteral drug abusers with AIDS than among those without AIDS. These findings, along with the absence of hepatitis delta antibodies in the drug abusers with AIDS, are probably related to the profound general immunosuppression that occurs in AIDS.

UI MeSH Term Description Entries
D007407 Interviews as Topic Works about conversations with an individual or individuals held in order to obtain information about their background and other personal biographical data, their attitudes and opinions, etc. It includes works about school admission or job interviews. Group Interviews,Interviewers,Interviews, Telephone,Oral History as Topic,Group Interview,Interview, Group,Interview, Telephone,Interviewer,Interviews, Group,Telephone Interview,Telephone Interviews
D003698 Hepatitis Delta Virus A defective virus, containing particles of RNA nucleoprotein in virion-like form, present in patients with acute hepatitis B and chronic hepatitis. It requires the presence of a hepadnavirus for full replication. This is the lone species in the genus Deltavirus. Delta Agent,Delta Virus,Deltavirus,Hepatitis D Virus,Delta Agents,Delta Virus, Hepatitis,Delta Viruses,Delta Viruses, Hepatitis,Deltaviruses,Hepatitis D Viruses,Hepatitis Delta Viruses
D003699 Hepatitis D INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Amazon Black Fever,Black Fever, Amazon,Delta Hepatitis,Delta Infection,Delta Superinfection,Hepatitis, Delta,Labrea Disease,Infection, Delta,Superinfection, Delta,Delta Superinfections,Disease, Labrea,Diseases, Labrea,Fever, Amazon Black,Hepatitides, Delta,Infections, Delta,Labrea Diseases,Superinfections, Delta
D006508 Hepatitis Antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis. Antibodies, Hepatitis
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral

Related Publications

M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
Prevalence of delta hepatitis markers among parenteral drug abusers and homosexual men with and without AIDS.
November 1991, Journal of hepatology,
M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
Acute delta hepatitis in Greek parenteral drug abusers.
January 1993, Progress in clinical and biological research,
M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
AIDS in haemophiliacs, parenteral drug abusers, and homosexuals.
February 1986, Lancet (London, England),
M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
Active viral B hepatitis in parenteral drug abusers with acquired immune deficiency syndrome (AIDS).
January 1989, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians,
M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
Seroprevalence of hepatitis B virus and delta agent in parenteral drug abusers. Immunogenicity of hepatitis B vaccine.
October 1986, The American journal of medicine,
M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
[Determinants of the prevalence of hepatitis B viral infection in parenteral drug abusers].
December 1993, Revista clinica espanola,
M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts.
November 1987, The New England journal of medicine,
M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
Prevalence of hepatitis B surface antigen (HBsAg) among parenteral drug abusers at Dhaka.
June 1989, Bangladesh Medical Research Council bulletin,
M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
Hepatitis B among parenteral drug abusers--North Carolina.
August 1986, MMWR. Morbidity and mortality weekly report,
M J Kreek, and D C Des Jarlais, and C L Trepo, and D M Novick, and A Abdul-Quader, and J Raghunath
Biphasic hepatitis in HBV/HDV coinfected parenteral drug abusers.
June 1986, Gut,
Copied contents to your clipboard!